Somatostatin receptor ligand
see also Somatostatin receptor PET ligands.
First-generation somatostatin receptors ligands (SRL) are the mainstay of acromegaly medical treatment, however, the percentage of patients controlled with these drugs significantly varies in the different studies.
Wildemberg et al. developed a machine learning-based prediction model with high accuracy that has the potential to improve acromegaly medical treatment, optimize biochemical control, decrease long-term morbidities and mortality and reduce health services costs 1)
1)
Wildemberg LE, da Silva Camacho AH, Miranda RL, Elias PCL, de Castro Musolino NR, Nazato D, Jallad R, Huayllas MKP, Mota JI, Almeida T, Portes E, Ribeiro-Oliveira A, Vilar L, Boguszewski CL, Winter Tavares AB, Nunes-Nogueira VS, Mazzuco TL, Rech CGSL, Marques NV, Chimelli L, Czepielewski M, Bronstein MD, Abucham J, de Castro M, Kasuki L, Gadelha M. Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands. J Clin Endocrinol Metab. 2021 Mar 4:dgab125. doi: 10.1210/clinem/dgab125. Epub ahead of print. PMID: 33686418.